Health 160's stock price plummeted 6.14% during intraday trading on Thursday, as the market continued to digest recent developments and engage in profit-taking.

The decline follows a period where previous positive catalysts, including the announcement that its 160 AI Hospital operational partnership model had signed 102 public medical institutions and the reporting of an adjusted net profit turnaround, were deemed to be fully priced into the stock. Despite the company authorizing a share repurchase plan for up to 10% of outstanding shares, the move failed to stem the selling pressure.

Market participants remain concerned about the company's fundamentals, particularly the pharmaceutical and health products segment where gross margins have long remained around 1.4%. The combination of these fundamental worries and the stock's excessive prior gains is exerting significant downward pressure, leading to a technical correction.